Understanding Very Early Onset Inflammatory Bowel Disease using whole exome sequencing: Functional analysis of novel candidates

使用全外显子组测序了解极早发炎症性肠病：新候选药物的功能分析

• 批准号: 302339
• 负责人: Li Qi
• 金额: $ 3.28万
• 依托单位: Hospital for Sick Children (Toronto)
• 依托单位国家: 加拿大
• 项目类别: Fellowship Programs
• 财政年份: 2013
• 资助国家: 加拿大
• 起止时间: 2013-11-01 至 2015-11-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=302339&lang=en
• 关键词: Next Generation Sequencing (Ngs); Nod2; Single Neucleotide Polymorphisms (Snps); Therapeutic Targets; Ubiquitylation; Very Early Onset Ibd (Veo-Ibd); Whole Exome Sequencing (Wes)

Inflammatory Bowel Disease (IBD) affects more people than many other common diseases such as diabetes. In Canada, the incidence of pediatric IBD has increased over the past decade by 5-7% per year. Moreover, those diagnosed under the age of 6, known as Ve

炎症性肠病（IBD）比许多其他常见疾病（如糖尿病）影响更多的人。在加拿大，儿童IBD的发病率在过去十年中每年增加5-7%。此外，那些被诊断为6岁以下的人，被称为Ve